Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma
European Journal of Cancer · 2023
DOI: 10.1016/j.ejca.2023.01.004 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Alexander C J van Akkooi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Melanoma Institute Australia, Sydney, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Royal Prince Alfred Hospita…. Hauptthemen laut MEDLINE: Nivolumab, Melanoma. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Melanoma Institute Australia, Sydney, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, Australia; Royal Prince Alfred Hospital, Sydney, Australia. Electronic address: alexander.vanakkooi@melanoma…
- Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Leiden University Medical Center, Faculty of Medicine, Leiden, the Netherlands.
- University Medical Center Utrecht & Princess Maxima Center, Utrecht, the Netherlands; Comprehensive Cancer Center München, Technical University München & Ludwig Maximiliaan University, München, Germany.
Zitieren
APA
van Akkooi, A. C. J., Blank, C., & Eggermont, A. M. M. (2023). Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.01.004
Vancouver
van Akkooi ACJ, Blank C, Eggermont AMM. Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.01.004
BibTeX
@article{vanAkkooi2023,
author = {van Akkooi, Alexander C J and Blank, Christian and Eggermont, Alexander M M},
title = {Neo-adjuvant immunotherapy emerges as best medical practice, and will be the new standard of care for macroscopic stage III melanoma},
journal = {European Journal of Cancer},
year = {2023},
doi = {10.1016/j.ejca.2023.01.004}
}
EUVIMED